Conditions: Parkinson Disease
Keywords: Parkinson Disease BIA 9-1067
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 27
Healthy volunteers: yes

Brief summary:
The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.

Detailed description:
Single-centre, open-label, randomised, two-way crossover study in healthy young male and female volunteers

Arms:
arm 1: Period 1: BIA 9-1067 + repaglinide Period 2: Repaglinide arm 2: Period 1: Repaglinide Period 2: BIA 9-1067 + repaglinide

Interventions: intervention 1: BIA 9-1067 intervention 2: Repaglinide
Intervention descriptions: intervention 1: 25 mg BIA 9-1067 (single-dose) intervention 2: 0.5 mg repaglinide (single-dose)

Protocol document: